An Introduction to Immunotherapy
Cancer immunotherapy has brought significant improvements for patients in terms of survival and quality of life. Monoclonal antibodies and immune checkpoint inhibitors are now an established part of the treatment paradigm for many types of cancer, but challenges remain around its efficacy, targeting and toxicity.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Emerging Targeted and Immunotherapies in Cholangiocarcinoma
Oncology & Hematology Review (US). 2019;15(2):71–5
Cholangiocarcinoma is an epithelial malignancy of the biliary system characterized by cholangiocyte differentiation, and its incidence is on the rise. Currently, cholangiocarcinomas are classified by their anatomical location in the biliary system as intrahepatic cholangiocarcinoma, distal cholangiocarcinoma, or hilar cholangiocarcinoma. Since 2010, the standard of care in all advanced, inoperable biliary tract cancers has been combination […]
PARP Inhibitors may be Beneficial in a Broader Range of Patients
Oncology & Hematology Review (US). 2019;15(2):66–7
Q. What is the role of PARP-1 in the pathogenesis of cancer? PARP-1 is a protein that resides in the cell nucleus where it plays a role in most, if not all, nuclear functions (e.g. DNA repair, transcription, RNA processing, RNA ribosomal transcription). PARP-1 uses these pathways to assist the cancer cell in its uncontrolled […]
Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy – the PSV™ Platform
Oncology & Hematology Review (US). 2019:15(2):64–5
Q. What are phosphopeptide tumor targets and why are they good candidates for vaccine and cell therapy development? PTTs are a novel class of neoantigen. They are portions of aberrantly phosphorylated proteins that are presented at the cell surface to the immune system in the context of human leukocyte antigen (HLA) class I molecules. These […]
Technical Challenges in the Manufacture of Dendritic Cell Cancer Therapies
European Oncology and Haematology. 2019;15(1):22–8 DOI: https://doi.org/10.17925/EOH.2019.15.1.22
Therapeutic cancer vaccination is a promising strategy that aims to treat late stage disease by using the patient’s own immune system.1 The immune system has the potential to eliminate cancer cells, since cancer cells express antigens that are unique to the tumour or are over-expressed in the tumour. However, despite many years of research, the effective […]
What’s on the horizon for treatment of solid tumours in 2019?
Watch leading clinicians with a broad range of oncology expertise discuss the current challenges in treating solid tumours, what they expect from the 2019 European Society of Medical Oncology (ESMO) Congress, 27 September–1 October 2019, and what the latest data could mean for global and regional clinical practice.
- Identify solid tumour types with the greatest unmet clinical need in terms of effective new therapy approaches
- Discuss emerging data for new immunotherapies and targeted therapies in solid tumours and know how to identify patients that may benefit from these new treatments
- Evaluate the rationales for different combination and sequential therapy approaches with new agents in solid tumours
IBRAHIM EL HOUSSIENY, EHA 2019 – CAR-T cells and manufacturing (Part 2)
Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 2 of his interview, part one can be viewed here. Questions 1. How can we mitigate the toxicities associated with CAR-T cell therapy? (0:05) 2. What is […]
IBRAHIM EL HOUSSIENY, EHA 2019 – CAR-T cells and manufacturing (Part 1)
Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 1 of his interview, part two can be viewed here. Questions 1. What have been the most exciting recent developments in CAR-T cell therapy? (0:05) 2. Which […]
Robin Foà MD, EHA 2019 – CAR-T cells in the treatment of haematological malignancies
At the EHA annual meeting in Amsterdam, Editorial Board member Robin Foà joins us to discuss the latest initiatives surrounding CAR-T cells and their use in the treatment of haematological malignancies. Questions 1. What are the major challenges to incorporating CAR-T cells into clinical practice? (0:06) 2. Where are CAR-T cells likely to fit into […]
Large-scale Genomic Testing Facilitates Precision Medicine in Routine Cancer Care
Oncology & Hematology Review. 2019;15(1):25–6 DOI: https://doi.org/10.17925/OHR.2019.15.1.25
Over the last decade, genomics has become an increasingly important part of cancer care. In some tumor types, such as lung cancer and melanoma, genetic profiling for actionable mutations has become standard clinical practice.1,2 The development of novel targeted molecular therapies together with the increased availability of next-generation genomic sequencing has led to an interest […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!